Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy
Open Access
- 21 June 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (6) , 760
Abstract
Background/Objectives: Lipid nanoparticles (LNPs) have emerged as crucial vehicles for messenger RNA (mRNA) applications in antitumor therapy. Combining LNPs with stimulator of interferon genes (STING) activation holds promise for treating “cold” tumors such as pancreatic cancer. However, two major challenges remain: inefficient mRNA escape from endosomes and STING pathway suppression in immunosuppressive tumor microenvironments. Methods: To improve endosomal escape, we developed a novel pH-responsive PEGylated lipid (Ben-mPEG2000) for mRNA-LNP preparation while using commercial Man-mPEG2000 for dendritic cell (DC)-targeted delivery of LNPs; to alleviate suppression of the STING pathway in the tumor microenvironment and activate immune responses, STING-R283S mRNA was encapsulated into LNPs, ultimately resulting in DC-targeted/pH-responsive LNPs loaded with STING-R283S mRNA for pancreatic cancer immunotherapy research. Results: After pH-responsive cleavage, Ben-mPEG2000 not only enhanced the positive charge of LNPs through the exposed protonated amino groups but also eliminated the PEG-induced steric hindrance effect. The combination of these two effects promoted membrane fusion between LNPs and the endosome, thereby enhancing mRNA translation. As a payload, STING-R283S could further amplify STING signaling in DCs without cytotoxicity to counteract immunosuppression in pancreatic cancer. Conclusions: This engineered LNP platform enhanced mRNA expression and STING activation in DCs, improving immunotherapy outcomes in pancreatic cancer.Keywords
Funding Information
- National Natural Science Foundation of China (82473891)
- National Natural Science Foundation of China (82304455)
- Natural Science Foundation of Shanghai Municipality (24ZR1449500)
This publication has 61 references indexed in Scilit:
- Strategies and mechanisms for endosomal escape of therapeutic nucleic acidsCurrent Opinion in Chemical Biology, 2024
- Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic CancerJAMA Oncology, 2022
- Type I interferon-mediated tumor immunity and its role in immunotherapyCellular and Molecular Life Sciences, 2022
- Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosisCancer Letters, 2021
- Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapyActa Pharmaceutica Sinica B, 2021
- Top 10 Challenges in Cancer ImmunotherapyImmunity, 2020
- Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell ImmunityCell, 2019
- Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STINGCell Reports, 2018
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and ImmunityCell Reports, 2015
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic TumorsImmunity, 2014